Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Viewpoint
Nature Reviews Nephrology 4, 366–367 (1 July 2008) | doi:10.1038/ncpneph0832
Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3|[ndash]|4 chronic kidney disease
&
Abstract
This, the second of two opposing Viewpoints, presents the case for the use of cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are not receiving dialysis. The authors assert that cinacalcet effectively reduces serum parathyroid hormone level in this setting, and that any adverse effects of the drug on calcium or phosphorus levels can be managed by monitoring and treating patients accordingly.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
